Ajanta Pharma Ltd

Ajanta Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ajanta Pharma Ltd

₹ 2,538 1.18%
26 Nov 4:01 p.m.
ajantapharma.com BSE: 532331 NSE: AJANTPHARM
About

Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

Key Points

India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]

Website BSE NSE
  • Market Cap ₹ 31,719 Cr.
  • Current Price ₹ 2,538
  • High / Low ₹ 3,116 / 2,022
  • Stock P/E 33.4
  • Book Value ₹ 330
  • Dividend Yield 1.10 %
  • ROCE 33.0 %
  • ROE 25.7 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 44.6%

Cons

  • Stock is trading at 7.63 times its book value
  • Promoter holding has decreased over last 3 years: -4.24%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE MidCap Nifty Pharma

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
837 875 849 1,015 945 1,085 926 1,077 1,129 1,102 1,014 1,209 1,220
676 715 704 738 672 758 699 761 826 766 764 879 931
Operating Profit 161 159 145 277 274 327 227 316 303 336 250 329 290
OPM % 19% 18% 17% 27% 29% 30% 25% 29% 27% 31% 25% 27% 24%
78 31 37 31 52 14 34 28 40 33 18 41 75
Interest 1 3 1 1 2 2 1 1 1 2 1 1 1
Depreciation 32 32 32 32 33 33 33 33 33 35 39 40 42
Profit before tax 207 155 148 275 290 305 226 311 309 332 228 329 322
Tax % 19% 20% 21% 23% 27% 28% 28% 24% 24% 24% 15% 22% 22%
167 124 117 212 212 220 163 236 235 252 193 255 250
EPS in Rs 13.05 9.67 9.15 16.55 16.57 17.18 12.70 18.90 18.81 20.21 15.49 20.41 19.97
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
1,110 1,356 1,574 1,804 1,825 1,773 2,196 2,719 3,141 3,411 3,971 4,322 4,545
764 884 1,044 1,166 1,279 1,291 1,664 1,800 2,246 2,710 2,852 3,117 3,340
Operating Profit 346 473 529 638 547 481 533 919 895 701 1,119 1,205 1,205
OPM % 31% 35% 34% 35% 30% 27% 24% 34% 28% 21% 28% 28% 27%
18 27 80 63 73 102 180 102 136 131 116 119 167
Interest 8 5 4 1 0 0 9 7 9 5 7 5 5
Depreciation 42 49 43 59 57 70 91 111 121 127 132 140 156
Profit before tax 313 445 563 641 562 513 613 902 901 700 1,097 1,180 1,211
Tax % 29% 31% 25% 22% 24% 24% 28% 25% 20% 20% 26% 22%
221 306 422 500 428 392 441 676 720 559 807 917 950
EPS in Rs 16.76 23.21 31.97 37.86 32.39 29.93 33.70 52.05 56.20 43.61 63.00 73.40 76.08
Dividend Payout % 16% 17% 17% 23% 0% 20% 26% 12% 11% 16% 80% 38%
Compounded Sales Growth
10 Years: 12%
5 Years: 15%
3 Years: 11%
TTM: 8%
Compounded Profit Growth
10 Years: 11%
5 Years: 15%
3 Years: 8%
TTM: 11%
Stock Price CAGR
10 Years: 11%
5 Years: 20%
3 Years: 27%
1 Year: -16%
Return on Equity
10 Years: 24%
5 Years: 23%
3 Years: 22%
Last Year: 26%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 18 18 18 18 18 18 18 17 17 25 25 25 25
Reserves 519 769 1,114 1,486 1,914 2,125 2,444 2,868 3,152 3,221 3,388 3,600 4,103
129 71 68 0 0 0 23 26 20 33 31 31 31
215 229 214 245 360 379 564 621 591 1,025 773 898 844
Total Liabilities 880 1,086 1,414 1,749 2,292 2,522 3,049 3,532 3,780 4,305 4,217 4,554 5,003
261 271 433 573 1,037 1,162 1,449 1,519 1,492 1,484 1,465 1,742 1,852
CWIP 94 170 240 339 61 261 131 108 153 209 256 176 146
Investments 79 77 94 199 201 83 86 157 165 553 367 482 892
446 568 647 638 993 1,015 1,383 1,748 1,970 2,058 2,129 2,154 2,112
Total Assets 880 1,086 1,414 1,749 2,292 2,522 3,049 3,532 3,780 4,305 4,217 4,554 5,003

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
190 263 277 537 219 312 301 467 542 736 735 1,054
-176 -146 -139 -340 -201 -137 -116 -163 -66 -501 105 -350
-20 -101 -128 -198 -1 -181 -134 -269 -457 -105 -1,048 -716
Net Cash Flow -6 16 9 -1 18 -6 51 35 19 130 -207 -12

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 58 65 81 68 86 87 122 105 121 105 111 104
Inventory Days 156 147 167 149 290 386 240 317 278 248 229 267
Days Payable 116 104 128 121 193 173 166 159 120 128 130 132
Cash Conversion Cycle 98 108 121 96 183 300 195 264 279 225 210 238
Working Capital Days 35 55 83 73 115 132 132 138 153 92 130 116
ROCE % 56% 60% 55% 48% 33% 25% 27% 34% 30% 21% 32% 33%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
66.11% 66.11% 66.22% 66.22% 66.22% 66.22% 66.27% 66.26% 66.26% 66.26% 66.26% 66.25%
10.07% 10.00% 10.19% 9.99% 9.11% 8.54% 8.36% 9.11% 9.26% 8.86% 8.86% 8.53%
15.37% 15.52% 15.36% 15.60% 16.67% 17.48% 17.41% 17.09% 17.02% 17.48% 17.50% 17.90%
0.45% 0.45% 0.46% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
8.00% 7.91% 7.78% 8.21% 8.00% 7.76% 7.94% 7.51% 7.45% 7.38% 7.38% 7.32%
No. of Shareholders 59,79883,54954,87456,27754,35155,48870,31664,31566,89670,82768,88267,785

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls